Wang Xue-Feng, Lin Yue-Zhi, Li Qiang, Liu Qiang, Zhao Wei-Wei, Du Cheng, Chen Jie, Wang Xiaojun, Zhou Jian-Hua
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, 150001, China.
Department of Preventive Veterinary Medicine, College of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
Retrovirology. 2016 Feb 3;13:9. doi: 10.1186/s12977-016-0240-6.
The equine infectious anemia virus (EIAV) vaccine is the only attenuated lentiviral vaccine applied on a large scale that has been shown to be effective in controlling the prevalence of EIA in China. This vaccine was developed by successive passaging of a field-isolated virulent strain in different hosts and cultivated cells. To explore the molecular basis for the phenotype alteration of this vaccine strain, we systematically analyzed its genomic evolution during vaccine development.
Sequence analysis revealed that the genetic distance between the wild-type strain and six representative strains isolated from key development stages gradually increased with the number of passages. Env gene, but not gag and pol, showed a clear evolutionary flow similar to that of the whole genomes of different generations during the attenuation. Stable mutations were identified in multiple regions of multiple genes along with virus passaging. The adaption of the virus to the growth environment of cultured cells with accumulated genomic and genetic variations was positively correlated with the reduction in pathogenicity and rise of immunogenicity. Statistical analyses revealed significant differences in the frequency of the most stable mutations between in vivo and ex vivo-adapted strains and between virulent and attenuated strains.
These data indicate that EIAV evolution during vaccine development generated an accumulation of mutations under the selective drive force, which helps to better understand the molecular basis of lentivirus pathogenicity and immunogenicity.
马传染性贫血病毒(EIAV)疫苗是唯一大规模应用的减毒慢病毒疫苗,在中国已被证明对控制EIA的流行有效。该疫苗是通过在不同宿主和培养细胞中对一株野外分离的强毒株进行连续传代而研制的。为了探索该疫苗株表型改变的分子基础,我们系统分析了其在疫苗研制过程中的基因组进化。
序列分析表明,野生型毒株与从关键研制阶段分离出的6株代表性毒株之间的遗传距离随着传代次数的增加而逐渐增大。Env基因而非gag和pol基因在减毒过程中呈现出与不同代次全基因组相似的明显进化趋势。随着病毒传代,在多个基因的多个区域鉴定出稳定的突变。病毒通过积累基因组和遗传变异来适应培养细胞的生长环境,这与致病性降低和免疫原性增强呈正相关。统计分析显示,体内适应株与体外适应株之间以及强毒株与减毒株之间最稳定突变的频率存在显著差异。
这些数据表明,EIAV在疫苗研制过程中的进化在选择性驱动力作用下产生了突变积累,这有助于更好地理解慢病毒致病性和免疫原性的分子基础。